MX2009013829A - Composiciones terapeuticas y su uso. - Google Patents

Composiciones terapeuticas y su uso.

Info

Publication number
MX2009013829A
MX2009013829A MX2009013829A MX2009013829A MX2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
therapeutic compositions
compositions
atazanavir
Prior art date
Application number
MX2009013829A
Other languages
English (en)
Spanish (es)
Inventor
Brian P Kearney
Anita A Mathias
Srinivasan Ramanathan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2009013829A publication Critical patent/MX2009013829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009013829A 2007-06-29 2008-06-26 Composiciones terapeuticas y su uso. MX2009013829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
MX2009013829A true MX2009013829A (es) 2010-03-10

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013829A MX2009013829A (es) 2007-06-29 2008-06-26 Composiciones terapeuticas y su uso.

Country Status (19)

Country Link
US (4) US20100331331A1 (enExample)
EP (1) EP2167088A1 (enExample)
JP (3) JP5547066B2 (enExample)
KR (1) KR20100040892A (enExample)
CN (2) CN101686972B (enExample)
AP (1) AP2965A (enExample)
AR (1) AR067183A1 (enExample)
AU (1) AU2008270630B2 (enExample)
BR (1) BRPI0813000A2 (enExample)
CA (1) CA2692101A1 (enExample)
CO (1) CO6251237A2 (enExample)
EA (1) EA200971093A1 (enExample)
EC (1) ECSP109897A (enExample)
IL (1) IL202744A0 (enExample)
MX (1) MX2009013829A (enExample)
NZ (1) NZ582086A (enExample)
SG (1) SG182229A1 (enExample)
TW (1) TW200914011A (enExample)
WO (1) WO2009006199A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
PL2049506T5 (pl) 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR067184A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (enExample) 2013-07-12 2018-07-21
WO2015120057A1 (en) * 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP1758581A1 (en) * 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
PL2049506T5 (pl) * 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
WO2008033836A2 (en) * 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR067184A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
AU2008270630B2 (en) 2014-01-16
ECSP109897A (es) 2010-03-31
US20100331331A1 (en) 2010-12-30
BRPI0813000A2 (pt) 2014-12-23
AR067183A1 (es) 2009-09-30
CN101686972A (zh) 2010-03-31
JP2010532372A (ja) 2010-10-07
KR20100040892A (ko) 2010-04-21
WO2009006199A1 (en) 2009-01-08
NZ582086A (en) 2012-07-27
AU2008270630A1 (en) 2009-01-08
US20170136001A1 (en) 2017-05-18
AP2965A (en) 2014-09-30
US20090093467A1 (en) 2009-04-09
JP5769763B2 (ja) 2015-08-26
EP2167088A1 (en) 2010-03-31
IL202744A0 (en) 2010-06-30
CO6251237A2 (es) 2011-02-21
CN103480000A (zh) 2014-01-01
JP2013199495A (ja) 2013-10-03
SG182229A1 (en) 2012-07-30
AP2009005074A0 (en) 2009-12-31
TW200914011A (en) 2009-04-01
JP5547066B2 (ja) 2014-07-09
CN101686972B (zh) 2013-08-14
US20140343063A1 (en) 2014-11-20
JP2015143278A (ja) 2015-08-06
EA200971093A1 (ru) 2010-08-30
CA2692101A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
MX2009013829A (es) Composiciones terapeuticas y su uso.
MX2009013828A (es) Composiciones terapeuticas y su uso.
PH12013502180A1 (en) Benzothiazole compounds and their pharmaceutical use
SG178952A1 (en) Chemical compounds
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
GEP201606555B (en) Compounds and compositions for modulating egfr activity
MX2012007076A (es) Terapia combinada de hcv.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
UA105556C2 (uk) Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
NZ604716A (en) 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
PH12014500386A1 (en) Combination treatment for hepatitis c
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
IN2012DN01855A (enExample)
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2007084435A3 (en) Methods for treating hepatitis c
WO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法